A new study has revealed significant insights into the molecular changes that accompany the progression of Alzheimer’s disease (AD), shedding new light on potential biomarkers and therapeutic targets. The study, which was published in Nature Neuroscience, shows different proteomic signatures that are linked to the buildup of amyloid-beta (Aβ) plaques and tau tangles, which are two of the most common problems in Alzheimer’s disease.
The study, led by a team of international researchers, analysed cerebrospinal fluid (CSF) samples from 877 participants as part of the BioFINDER-2 cohort. These participants were categorised based on their Aβ and tau pathology status, allowing the researchers to map the proteomic landscape across different stages of Alzheimer’s disease. By combining CSF proteomics with advanced imaging techniques, such as positron emission tomography (PET), the researchers were able to identify proteins that are differentially abundant throughout the disease continuum.
One of the study’s key findings is the identification of 127 differentially abundant proteins (DAPs) across the AD spectrum. These proteins exhibit distinct patterns depending on whether a person has Aβ plaques, tau tangles, or both. Notably, the study found that certain proteins, such as SMOC1 and ITGAM, are significantly associated with Aβ pathology and are primarily expressed in glial cells. These findings suggest that glial cells play a crucial role in the early stages of Alzheimer’s disease, particularly in the formation of Aβ plaques.
The study also highlights the involvement of proteins related to ATP metabolism, which are predominantly expressed in neurons. These proteins, including those involved in energy production and cellular stress responses, were found to be independently associated with tau pathology. The presence of these proteins was more pronounced as the disease progressed, particularly when both Aβ plaques and tau tangles were present.
One of the most significant aspects of this research is its potential impact on the development of new therapeutic strategies for Alzheimer’s disease. The distinct proteomic profiles identified in this study could serve as valuable biomarkers for diagnosing and staging the disease. Furthermore, the study’s findings open new avenues for targeted treatments aimed at specific stages of Alzheimer’s progression.
The researchers emphasised that only a small fraction of the identified DAPs were also altered in other neurodegenerative diseases, underscoring the specificity of these proteins to Alzheimer’s disease. This specificity could prove crucial in developing targeted therapies that address the unique molecular changes associated with Alzheimer’s, rather than more generalised approaches to neurodegeneration.
